File photo shows a staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing. (Xinhua File/Zhang Yuwei) 

A phase 2 trial of a COVID-19 vaccine candidate in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.